Maruxa pill coated 10mg N60
Condition: New product
1000 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Memantine
Release form
Pills
Composition
Memantine hydrochloride 10 mg. Excipients: lactose monohydrate 51.45 mg, microcrystalline cellulose 175 mg, colloidal silicon dioxide 2.5 mg, talc 9.8 mg, magnesium stearate 1.25 mg. The composition of the film shell: methacrylic acid and ethyl acrylate copolymer (1: 1), 30% aqueous dispersion, 0.6 mg (in terms of dry substance. Also contains sodium lauryl sulfate and polysorbate-80 as emulsifiers), talc 0.27 mg, triacetin 0.12 mg, Simethicone 0.01 mg.
Pharmacological effect
Remedy for the treatment of dementia. It is a noncompetitive antagonist of glutamate NMDA receptors (including in the substantia nigra), thereby reducing the excessive stimulating effect of cortical glutamate neurons on neostriatum, which develops against the background of insufficient release of dopamine. Reducing the entry of Ca2 + into neurons reduces the possibility of their destruction. It has nootropic, cerebrovasodilating, antihypoxic and psychostimulating action. It improves impaired memory, increases the ability to concentrate, reduces fatigue and symptoms of depression, reduces spasticity of skeletal muscles caused by diseases or damage to the brain.
Indications
Dementia moderate to severe with Alzheimer's disease
Contraindications
Classification of the incidence of side effects WHO: very often - & # 8805 .1 / 10. often from & # 8805 .1 / 100 to <1/10. Infrequently - from & # 8805 .1 / 1000 to <1/100. rarely from & # 8805 .1 / 10,000 to <1/1000. very rarely - <1/10000. frequency unknown - cannot be estimated based on available data. In clinical studies, the overall incidence of adverse reactions did not differ when memantine and placebo were taken. They were generally mild to moderate in severity. The most frequent adverse reactions in the memantine group compared with placebo were: dizziness (6.3 versus 5.6%, respectively), headache (5.2 versus 3.9%), constipation (4.6 versus 2.6%) , drowsiness (3.4 versus 2.2%) and arterial hypertension (4.1 versus 2.8%). Side effects are classified by MedDRA. Infectious and parasitic diseases: rarely - fungal infections. On the part of the immune system: often - hypersensitivity to the components of the drug. Psychiatric disorders: often - drowsiness. infrequently - confusion, hallucinations *. frequency unknown - psychotic reactions. On the part of the nervous system: often - dizziness, imbalance. infrequently - gait disturbance. very rarely - seizures. From the side of the heart: infrequently - heart failure.On the part of the vessels: often - increase in blood pressure. infrequently - venous thrombosis / thromboembolism. The respiratory system, organs of the chest and mediastinum: often - shortness of breath. On the part of the digestive tract: often - constipation. infrequently - nausea, vomiting. frequency is unknown - pancreatitis. On the part of the liver and biliary tract: often - increased activity of liver enzymes. frequency unknown - hepatitis. General disorders and disorders at the injection site: often - headache. infrequently - fatigue. * Hallucinations have been observed mainly in patients with Alzheimer's disease at the stage of severe dementia. In post-registration use, the following adverse reactions were reported: dizziness, drowsiness, irritability, fatigue, anxiety, increased ICP, nausea, hallucinations, headache, impaired consciousness, muscle tone, gait disturbance, depression, convulsions, psychotic reactions, suicidal thoughts , constipation, nausea, pancreatitis, candidiasis, increased blood pressure, vomiting, cystitis, increased libido, venous thrombosis, thromboembolism and allergic reactions.
Use during pregnancy and lactation
Due to the possible delay in intrauterine development, Maroux's drug is not used during pregnancy. There is no information about the allocation of memantine with breast milk. However, given the lipophilicity of memantine, excretion is possible. Therefore, at the time of treatment with Maruxa, breastfeeding should be stopped.
Dosage and administration
Inside, 1 time per day and always at the same time, regardless of the meal. Therapy should be carried out under the supervision of a physician with expertise in the diagnosis and treatment of dementia in Alzheimer's disease. Therapy should be initiated only if the person who regularly cares for the patient will monitor their drug intake. The diagnosis should be made in accordance with the current recommendations. You should regularly assess the tolerability and dose of the drug Maruxa, preferably within 3 months. after initiation of therapy. Then you should regularly evaluate the clinical efficacy of the drug and the tolerability of therapy in accordance with the current clinical guidelines. Maintenance therapy can be continued indefinitely in the presence of a therapeutic effect and good tolerability of the drug Marux.The use of Maruxa should be discontinued if the therapeutic effect is no longer observed or the patient does not tolerate therapy. In order to reduce the risk of side effects, a gradual increase in the dose is recommended: 5 mg / week. during the first 3 weeks. therapy. The recommended maintenance dose is 20 mg / day. The following dosing regimen is recommended: 1st week. (1–7th day): daily dose - 5 mg (1⁄2 pills. Marux 10 mg every day for 7 days). 2nd week (8–14th day): daily dose - 10 mg (1 tab. Marux 10 mg every day for 7 days). 3rd week (15–21st day): daily dose - 15 mg (11⁄2 pills. Maroux 10 mg every day for 7 days). Starting from the 4th week: daily dose - 20 mg (2 pills. Marux 10 mg each day).
Side effects
Classification of the incidence of side effects of the World Health Organization (WHO): very often> 1/10 often from> 1/100 to <1/10 rarely from> 1/1000 to <1/100 rarely from> 1/10000 to <1 / 1000 very rarely <1/10000 frequency unknown cannot be estimated based on available data. In clinical studies, the overall incidence of adverse reactions did not differ when memantine and placebo were taken. They were generally mild to moderate in severity. The most frequent adverse reactions in the memantine group compared with placebo were: dizziness (6.3% versus 5.6%, respectively), headache (5.2% versus 3.9%), constipation (4.6% versus 2 , 6%), drowsiness (3.4% versus 2.2%, respectively) and arterial hypertension (4.1% versus 2.8%, respectively). Infectious and parasitic diseases: rarely - fungal infections. Violations of the blood and lymphatic system: the frequency is unknown - agranulocytosis, leukopenia (including neutropenia), pancytopenia, thrombocytopenia, thrombocytopenic purpura. Immune system disorders: often - hypersensitivity to the components of the drug. Psychiatric disorders: often - drowsiness. infrequently - confusion, hallucinations. frequency unknown - psychotic reactions. Nervous system disorders: often - dizziness, imbalance. infrequently - gait disturbance. very rarely - seizures. Heart disorders: Infrequently - heart failure. Vascular disorders: often - increased blood pressure. infrequently - venous thrombosis / thromboembolism. Disturbances from the respiratory system, organs of the chest and mediastinum: often - shortness of breath. Disorders of the gastrointestinal tract: the frequency is unknown - pancreatitis.Violations of the liver and biliary tract: often - increased activity of "liver" transaminases. frequency unknown - hepatitis. Kidney and urinary tract disorders: frequency unknown - acute renal failure. Violations of the skin and subcutaneous tissues: the frequency is unknown - Stevens-Johnson syndrome. General disorders and disorders at the injection site: often - headache. infrequently - fatigue. Hallucinations have been observed mainly in patients with Alzheimer's disease at the stage of severe dementia. In post-registration use of Maruxa, the following adverse reactions were reported: dizziness, drowsiness, anxiety, fatigue, anxiety, increased intracranial pressure, nausea, hallucinations, headache, impaired consciousness, muscle tone, impaired gait, depression, convulsions, psychotic reactions, suicidal thoughts, constipation, nausea, pancreatitis, candidiasis, increased blood pressure, vomiting, cystitis, increased libido, venous thrombosis, thromboembolism and allergies cal reactions.
special instructions
Classification of the incidence of side effects of the World Health Organization (WHO): very often> 1/10 often from> 1/100 to <1/10 rarely from> 1/1000 to <1/100 rarely from> 1/10000 to <1 / 1000 very rarely <1/10000 frequency unknown cannot be estimated based on available data. In clinical studies, the overall incidence of adverse reactions did not differ when memantine and placebo were taken. They were generally mild to moderate in severity. The most frequent adverse reactions in the memantine group compared with placebo were: dizziness (6.3% versus 5.6%, respectively), headache (5.2% versus 3.9%), constipation (4.6% versus 2 , 6%), drowsiness (3.4% versus 2.2%, respectively) and arterial hypertension (4.1% versus 2.8%, respectively). Infectious and parasitic diseases: rarely - fungal infections. Violations of the blood and lymphatic system: the frequency is unknown - agranulocytosis, leukopenia (including neutropenia), pancytopenia, thrombocytopenia, thrombocytopenic purpura. Immune system disorders: often - hypersensitivity to the components of the drug. Psychiatric disorders: often - drowsiness. infrequently - confusion, hallucinations. frequency unknown - psychotic reactions. Nervous system disorders: often - dizziness, imbalance. infrequently - gait disturbance. very rarely - seizures. Heart disorders: Infrequently - heart failure.Vascular disorders: often - increased blood pressure. infrequently - venous thrombosis / thromboembolism. Disturbances from the respiratory system, organs of the chest and mediastinum: often - shortness of breath. Disorders of the gastrointestinal tract: the frequency is unknown - pancreatitis. Violations of the liver and biliary tract: often - increased activity of "liver" transaminases. frequency unknown - hepatitis. Kidney and urinary tract disorders: frequency unknown - acute renal failure. Violations of the skin and subcutaneous tissues: the frequency is unknown - Stevens-Johnson syndrome. General disorders and disorders at the injection site: often - headache. infrequently - fatigue. Hallucinations have been observed mainly in patients with Alzheimer's disease at the stage of severe dementia. In post-registration use of Maruxa, the following adverse reactions were reported: dizziness, drowsiness, anxiety, fatigue, anxiety, increased intracranial pressure, nausea, hallucinations, headache, impaired consciousness, muscle tone, impaired gait, depression, convulsions, psychotic reactions, suicidal thoughts, constipation, nausea, pancreatitis, candidiasis, increased blood pressure, vomiting, cystitis, increased libido, venous thrombosis, thromboembolism and allergies cal reactions.